Group 1 - The company will hold its second extraordinary general meeting of shareholders on November 25, 2025, to discuss additional proposals [1][3] - Zhejiang International Trade Group Co., Ltd., the controlling shareholder, proposed to add a temporary proposal regarding the loan limit to the company's subsidiary [2][19] - The proposal has been approved by the independent directors and the board of directors, and it complies with relevant laws and regulations [2][19] Group 2 - The loan amount proposed is 1.3 billion yuan, intended for daily operations and debt replacement, with a validity period until July 20, 2026 [13][19] - The loan interest rate will not exceed 3.15% and will be subject to the weighted average interest rate of bank loans at the time of borrowing [13][19] - The board meeting on November 13, 2025, approved the proposal with a unanimous vote, excluding the related director from voting [42][43] Group 3 - The company is also establishing the "Oriental Zheyao Zhongying Binjiang Medical Fund" with a target size of 500 million yuan, involving several partners [21][22] - The fund will focus on supporting the biopharmaceutical and medical device industries, with a management fee of 0.75% per year during the investment period [31][38] - The fund's investment strategy includes a cap on single investments and a focus on mid to late-stage projects [33][38]

Core Points - Zhejiang Dongfang announced a board meeting on November 13, 2025, to approve a loan limit for its subsidiary, Guojin Leasing, from its controlling shareholder, Zhejiang International Trade Group [2] - The loan amount is set at 1.3 billion yuan, intended for daily operations and debt replacement, with a validity period until July 20, 2026 [2] - The loan can be reused within the validity period, with an interest rate not exceeding 3.15% and not higher than the weighted average bank borrowing rate at the time of borrowing [2] - The loan term will not exceed three years, and the transaction is classified as a related party transaction, pending shareholder approval [2]

Core Viewpoint - Zhejiang Dongfang (600120.SH) announced the establishment of the Dongfang Zheyao Fund, with a total fundraising target of 500 million yuan [1] Group 1: Fund Structure - The fund will be managed by Dongfang Chanrong, a wholly-owned subsidiary of Zhejiang Dongfang, in collaboration with Bank of China Asset Management, High-tech Jin Investment, and Zhejiang Pharmaceutical Group [1] - Dongfang Chanrong will act as the controlling shareholder, while Zhejiang Pharmaceutical Group's wholly-owned subsidiary, Hanting Capital, will co-establish a new pharmaceutical fund management company [1] Group 2: Investment Contributions - Bank of China Asset Management's wholly-owned subsidiary, Bank of China Capital Private Fund Management (Beijing) Co., Ltd. will serve as the second general partner (GP2) [1] - The investment contributions from limited partners include: - Chanrong Huiying: 119.2 million yuan (23.84%) - Zhejiang Pharmaceutical Group: 29.8 million yuan (5.96%) - Bank of China Asset Management: 149 million yuan (29.8%) - High-tech Jin Investment's subsidiary, Hangzhou High-tech (Rights Protection) Venture Capital Co., Ltd.: 200 million yuan (40%) [1]

Core Viewpoint - Zhejiang Dongfang (600120.SH) announced the establishment of the Dongfang Zheyao Fund, with a total fundraising target of 500 million yuan, aimed at investing in the pharmaceutical sector [1] Group 1: Fund Structure - Dongfang Chanyun, a wholly-owned subsidiary of Zhejiang Dongfang, will act as the fund manager [1] - The fund will be jointly established with partners including Bank of China Asset Management, High-tech Jin Investment, and Zhejiang Pharmaceutical Group [1] - The fund management company will be a joint venture between Dongfang Chanyun and a wholly-owned subsidiary of Zhejiang Pharmaceutical Group, Hanting Capital [1] Group 2: Capital Contributions - The total fundraising scale is set at 500 million yuan, with various partners contributing different amounts [1] - Limited partners include: - Chanyun Huiying: 119.2 million yuan (23.84%) - Zhejiang Pharmaceutical Group: 29.8 million yuan (5.96%) - Bank of China Asset Management: 149 million yuan (29.8%) - High-tech Jin Investment's subsidiary, Hangzhou High-tech Venture Capital: 200 million yuan (40%) [1]

Core Viewpoint - Zhejiang Dongfang announced the establishment of the "Dongfang Zhe Pharmaceutical Zhongying Binjiang Medical Fund" through a subsidiary, indicating a strategic move to enhance its investment portfolio and engage in related transactions [1] Company Summary - The company's revenue composition for the year 2024 is as follows: futures business accounts for 82.69%, financing leasing for 5.48%, other businesses for 4.21%, insurance for 4.07%, and trust business for 3.31% [1] - As of the report, Zhejiang Dongfang has a market capitalization of 23.7 billion yuan [1]

| 股票代码：600120 | 证券简称：浙江东方 | | | 编号：2025-062 | | --- | --- | --- | --- | --- | | 债券代码：138898.SH | 债券简称：23 | 东方 | 01 | | | 债券代码：240620.SH | 债券简称：24 | 东方 | 01 | | | 债券代码：241264.SH | 债券简称：24 | 东方 | K1 | | | 债券代码：241781.SH | 债券简称：24 | 东方 | 03 | | 浙江东方金融控股集团股份有限公司 关于关联方向公司控股子公司提供借款额度暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要事项提示： ● 本次关联交易系浙江东方金融控股集团股份有限公司（以下简称"公司"） 控股股东浙江省国际贸易集团有限公司（以下简称"省国贸集团"）向公司控股 子公司浙江国金融资租赁股份有限公司（以下简称"国金租赁"）提供借款额度 13 亿元，用于日常经营及债务置换，额度有效期至 2026 年 7 月 20 日，有效 ...

浙江东方金融控股集团股份有限公司 与私募基金合作投资暨关联交易公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江东方金融控股集团股份有限公司（以下简称"浙江东方"或"公司"） 旗下全资子公司浙江东方集团产融投资有限公司（简称"东方产融"）拟作为 基金管理人，联合中银金融资产投资有限公司（简称"中银资产"）、杭州高 新金投控股集团有限公司（简称"高新金投"）、浙江省医药健康产业集团有 限公司（简称"浙药集团"）等发起设立"东方浙药中瀛滨江医药扶摇基金" （简称"东方浙药基金"或"基金"），基金规模拟定 5 亿元。东方产融全资 子公司桐乡市产融慧盈股权投资有限公司（简称"产融慧盈"）作为有限合伙 人，认缴 1.192 亿元基金份额，并由东方产融出资 800 万元与浙药集团全资子公 司浙江汗青投资股权有限公司（以下简称"汗青资本"）共同成立合资公司（以 下简称"医药基金管理公司"）作为基金执行事务合伙人之一，认缴 100 万元 基金份额。 根据《上海证券交易所股票上市规则》等相关法律法规及公司章程的 有关规定 ...

一、 股东会有关情况 | 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | Ａ股 | 600120 | 浙江东方 | 2025/11/18 | 二、 增加临时提案的情况说明 1. 提案人：浙江省国际贸易集团有限公司 2. 提案程序说明 证券代码：600120 证券简称：浙江东方 公告编号：2025-063 浙江东方金融控股集团股份有限公司 关于2025年第二次临时股东会增加临时提案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司已于2025 年 10 月 29 日公告了股东会召开通知，持有41.14%股份的公 司控股股东浙江省国际贸易集团有限公司，在2025 年 11 月 13 日提出临时提案 并书面提交股东会召集人。股东会召集人按照《上市公司股东会规则》有关规定， 现予以公告。 1. 股东会的类型和届次： 2025年第二次临时股东会 2. 股东会召开日期：2025 年 11 月 25 日 3. 股权登记日 3. 临时提案的具体内容 2025 年 11 ...

| 证券代码：600120 | 证券简称：浙江东方 | | | 公告编号：2025-060 | | --- | --- | --- | --- | --- | | 债券代码：138898.SH | 债券简称：23 | 东方 | 01 | | | 债券代码：240620.SH | 债券简称：24 | 东方 | 01 | | | 债券代码：241264.SH | 债券简称：24 | 东方 | K1 | | | 债券代码：241781.SH | 债券简称：24 | 东方 | 03 | | 浙江东方金融控股集团股份有限公司 十届董事会第二十一次会议决议公告 经董事会审议，同意公司全资子公司浙江东方集团产融投资有限公司（以下 简称"东方产融"）联合关联方浙江省医药健康产业集团有限公司（以下简称"浙 药集团"）、中银金融资产投资有限公司（简称"中银资产"）等发起设立"东 方浙药中瀛滨江医药扶摇基金"，基金募集资金不超过 5 亿元。其中，东方产融 作为基金管理人，并出资 800 万元和浙药集团全资子公司浙江汗青投资股权有限 公司合资新设医药基金管理公司（注册资本 1,000 万元）作为执行事务合伙人之 一，认缴 100 万 ...

格隆汇11月13日｜浙江东方公告称，公司十届董事会二十一次会议审议通过两项议案。一是同意全资子 公司东方产融联合关联方等发起设立"东方浙药中瀛滨江医药扶摇基金"，基金募资不超5亿元。东方产 融作为管理人，其及指定子公司共认缴1.212亿元，占比24.04%，浙药集团认缴0.298亿元，占比 5.96%。二是同意控股股东向控股子公司国金融资租赁提供13亿元借款额度，用于日常经营及债务置 换，有效期至2026年7月20日，年利率不高于3.15%，借款期限不超3年，该议案需提交股东会审议。 ...